Patau syndrome quad screen - patau syndrome screening - Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Patau Syndrome quad screening

Patau Syndrome Detection With Quad Screens Is Ineffective: How NIPT Methods Fill the Gap

NIPT (non-invasive prenatal testing) is an innovative genetic screening test allowing for early detection of the most common fetal aneuploidies, including Patau Syndrome (trisomy 13), Edwards' Syndrome (trisomy 18), and Down Syndrome (trisomy 21). Patau syndrome cannot be diagnosed through quad screens. Moreover, while traditional prenatal trisomy syndrome screening tests are among the most-prescribed diagnostic screening procedures for high-risk pregnancies, the risks associated with amniocentesis are frequently a source of patient trepidation. NIPT kits allow for trisomy 13 screening that is remarkably accurate and risk-free. This is a more a genuine medical breakthrough than Patau syndrome quad screening.

Prenatal trisomy syndrome screening is now safer than ever. The simple-to-prescribe Patau syndrome screening test developed by Eurofins Biomnis uses cell-free DNA thanks to a sampling of maternal blood, and presents zero risks. Moreover, this non-invasive prenatal sampling method has greater sensitivity and specificity when compared to serum marker screening, yielding unusual accuracy. While this non-invasive Patau syndrome screening methodis remarkably sensitive and specific, it is classified as an approved screening option for pregnant women at heightened risk of other common trisomies (18 and 21). In the case of a positive result for one or more pathologies, an invasive procedure such as amniocentesis is administered to confirm the diagnosis.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%